Apricot Capital logo

Apricot Capital

Asia, Shanghai, China, Shanghai

Description

Apricot Capital is an investment firm focused on investing in companies in the early and growing stages of the healthcare industry.

Investor Profile

Apricot Capital has made 3 investments, with 1 in the past 12 months and 33% as lead.

Stage Focus

  • Series D (33%)
  • Series Unknown (33%)
  • Seed (33%)

Country Focus

  • China (67%)
  • United States (33%)

Industry Focus

  • Biopharma
  • Biotechnology
  • Health Care
  • Life Science
  • Therapeutics
  • Medical
  • Medical Device
  • Precision Medicine
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Apricot Capital frequently co-invest with?

OrbiMed
North America, New York, United States, New York
Co-Investments: 1
Loyal Valley Capital
Asia, Shanghai, China, Shanghai
Co-Investments: 1
Lake Bleu Capital
Asia, Hong Kong Island, Hong Kong, Hong Kong
Co-Investments: 1
AC
Asia, Hong Kong Island, Hong Kong, Central
Co-Investments: 1
K. Wah Group
Asia, Hong Kong Island, Hong Kong, Hong Kong
Co-Investments: 1
CCB Capital
Asia, Beijing, China, Beijing
Co-Investments: 1
BOCOM International
Asia, Hong Kong Island, Hong Kong, Central
Co-Investments: 1
Shenzhen Capital Group
Asia, Hunan, China, Nanshan
Co-Investments: 1
Sino Biopharmaceutical
Asia, Hong Kong Island, Hong Kong, Wan Chai
Co-Investments: 1
CI
Asia, Hong Kong Island, Hong Kong, Hong Kong
Co-Investments: 1

What are some of recent deals done by Apricot Capital?

Sieran Medical

Suzhou, Jiangsu, China

Sieran Medical is a medical device company that specializes in minimally invasive surgical treatment solutions for ophthalmology.

MedicalMedical DevicePrecision Medicine
SeedSep 5, 2024
Amount Raised: $14,099,798
Akeso Biopharma

Zhongshan, Anhui, China

Akeso Biopharma is a biopharmaceutical company committed to the discovery, development, and commercialization of therapies.

BiopharmaBiotechnologyHealth Care
Series DNov 4, 2019
Amount Raised: $150,000,000
Ambrx

La Jolla, California, United States

Ambrx is a clinical-stage biopharmaceutical company using expanded genetic code technology for next-gen therapies and immune modulation.

BiopharmaBiotechnologyHealth CareLife ScienceTherapeutics
Series UnknownAug 4, 2016
Amount Raised: $45,000,000